Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 8,204

Document Document Title
WO/2024/120275A1
The present invention provides a preparation method for Edoxaban or a salt or hydrate thereof. The method comprises the following steps: step 1: under acidic conditions and in a polar solvent, removing the N-Boc protecting group of chemi...  
WO/2024/121261A1
Compounds of formula (I) wherein the substituents are as defined in claim 1, and the salts, stereoisomers, enantiomers, tautomers and N-oxides of those compounds, can be used as insecticides.  
WO/2024/122617A1
The present invention provides a compound having an antagonist and/or inverse agonist action on the serotonin 5-HT2A receptor as well as an antagonist and/or inverse agonist action on the serotonin 5-HT2C receptor, or a pharmaceutically ...  
WO/2024/115338A1
A compound of formula (I): [(Fu)r-L]s-(NFA)t, Fu is a fullerene; NFA is a non-fullerene acceptor; L is a linker group; r, s and t are each at least 1; and NFA is a non-fullerene acceptor. The NFA contains electron-accepting groups, elect...  
WO/2024/118858A1
Provided are compounds of Formula I, Formula Ia and Formula Ib and the pharmaceutically acceptable salts, esters, and prodrugs thereof, which are DGAT2 inhibitors. Also provided are methods of making compounds of Formula I, Formula Ia an...  
WO/2024/115733A1
The present invention relates to a compound of formula (I), or a tautomer, a stereoisomer, a hydrate, a solvate, a polymorph, a prodrug, an isotope, or a co-crystal thereof, or a pharmaceutically acceptable salt thereof, (I) wherein A, R...  
WO/2024/114639A1
The application relates to a compound of Formula (I) or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, which degrades HuR, a pharmaceutical composition comprising a compound of Formula (...  
WO/2024/112611A1
Provided are compounds that may bind a target protein, and result in modification of the target protein. The compounds may further bind a modifier protein. The modifier protein may carry out or enhance the modification of the target prot...  
WO/2024/108670A1
Disclosed are an edoxaban key intermediate and a synthesis method therefor. The edoxaban key intermediate is shown as (1) and is prepared by means of an ammonolysis reaction of raw materials. The intermediate can be used for preparing ed...  
WO/2024/107778A1
Disclosed is a compound represented by formula (I) or a pharmaceutically acceptable salt thereof. Compounds of formula (I) are useful for treating coronavirus infection via inhibition of the protease Mpro.  
WO/2024/105364A1
The present invention relates to compounds of formula (I). The compounds may be used to inhibit Cdc-Like Kinases, and thereby treat cancer, inflammatory disease, neurodegenerative disease, infection, tendinopathy, Duchenne muscular dystr...  
WO/2024/103123A1
Described herein are improved methods of making Compound 1 (4S,7S,10aS)-4-((S)-2- mercapto-3-phenylpropanamido)-5-oxooctahydro-7H-pyrido[2,1-b ][1,3]thiazepine-7-carboxylic acid, or Omapatrilat, and purified Omapatrilat obtained from the...  
WO/2024/098273A1
An anti-influenza virus phosphate ester compound and a use thereof. The phosphate ester compound is a compound represented by formula (I) below or a hydrate, a solvate, an optical isomer, a polymorph, an isotope derivative or a pharmaceu...  
WO/2024/098735A1
The present application belongs to the technical field of organic electroluminescence, and relates to an organic compound, and an organic electroluminescent apparatus and an electronic device using same. The organic compound has a struct...  
WO/2024/099438A1
Disclosed in the present invention are compounds as SUMO activating enzyme inhibitors. Particularly, the present invention relates to compounds as represented by general formula (1) and general formula (2) and preparation methods therefo...  
WO/2024/099386A1
The present application relates to the field of pharmaceutical chemistry, relates to a fused bicyclic compound, and in particular relates to a compound represented by formula (II), a stereoisomer or a pharmaceutically acceptable salt the...  
WO/2024/099898A1
The invention relates to substituted bi- and tricycles of the general formula (I),and the use of the compounds of the present invention as inhibitorsof HSET for the treatment and/or prevention of hyperproliferative diseases and disorders...  
WO/2024/099478A1
A selective inhibitor of PI3Kδ, and a free base, isomer, solvate, pharmaceutically acceptable salt and other structural forms thereof. The compounds have significant antagonistic activity on PI3Kδ, and a pharmacokinetic study shows tha...  
WO/2024/097296A1
Provided herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein)...  
WO/2024/097172A1
The disclosure relates to compounds of Formula (I) as allosteric chromenone inhibitors of phosphoinositide 3‑kinase (PI3K) useful in the treatment of diseases or disorders associated with PI3K modulation, Formula (I): (I) or pharmaceut...  
WO/2024/088189A1
The present disclosure provides a compound of formula (I), a pharmaceutical composition thereof, and a use thereof in treating and/or preventing diseases or disorders related to CDK9 kinase activity.  
WO/2024/088407A1
Disclosed are a nitrogen-containing fused ring compound as shown in formula (I), an intermediate thereof, a preparation method therefor and the use thereof. The compound has a DNA polymerase θ inhibitory activity, and can be used for tr...  
WO/2024/090469A1
The present invention addresses the problem of providing a pharmaceutical composition, particularly a compound that is suitable for preventing and/or treating inflammatory diseases and/or neurodegenerative diseases. The inventors of th...  
WO/2024/046471A9
The present application provides a class of novel compounds having a USP1 inhibitory activity as shown in formula (II'), pharmaceutical compositions comprising the compounds, useful intermediates for preparing the compounds, and a method...  
WO/2024/082959A1
The present invention discloses aggregation-induced emission fluorescent compounds with near-infrared (NIR) emission. This fluorescent compound is then encapsulated by polymer matrix to yield nanoaggregates which is confirmed to show an ...  
WO/2024/083980A1
The invention relates to novel compounds of the general formula (I-A) as defined in the application and pharmaceutical compositions comprising them and the use thereof as medicaments, in particular for the use as ferroportin inhibitors, ...  
WO/2024/086252A1
The present disclosure relates to compounds of general formula (I) or a pharmaceutically acceptable salt, solvate and/or hydrate thereof, methods for their preparation, the use of said compounds for use as a medicament, and their use in ...  
WO/2024/086634A1
The application relates to heterocyclic heteroaromatic macrocyclic ether compounds of the general Formula (I), pharmaceutically acceptable salts of the compounds and pharmaceutical compositions thereof. The compounds act as selective inh...  
WO/2024/083223A1
The present disclosure relates to macrocyclic compounds and the medical use thereof, the structures of the macrocyclic compounds being represented as formula (I). The present disclosure also relates to a method for preparing the compound...  
WO/2024/082958A1
The present invention discloses aggregation-induced emission fluorescent compounds with near-infrared (NIR) emission. The present invention also shows application for imaging-guided phototheranostic with the integration of both photodyna...  
WO/2024/077391A1
Compounds, compositions and their use in the treatment of a proliferative disease or condition such as a said proliferative disease or disorder associated with a RAF gene mutation and/or a RAS gene mutation. The compounds disclosed are o...  
WO/2024/076300A1
Compounds of the general formula (I) as described and defined herein, in particular compounds of formula (II), methods for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of sa...  
WO/2024/075696A1
The present invention addresses the problem of providing a novel compound having an SMG1 inhibitory activity and an anticancer effect, or a pharmaceutically acceptable salt thereof etc. A compound represented by formula (1) or a pharma...  
WO/2024/073658A1
The subject matter described herein is directed to myelin-promoting compounds of Formula (I) and pharmaceutical salts thereof, methods of preparing the compounds, pharmaceutical compositions comprising the compounds, and methods of admin...  
WO/2024/071398A1
The purpose of the present invention is to provide a drug for the prevention and/or treatment of diseases associated with ABHD6, said drug containing a compound having ABHD6 inhibitory activity as an active ingredient. A compound represe...  
WO/2024/072794A1
The invention provides pyridine carboxamide compounds, pharmaceutical compositions, and their use in treating medical conditions.  
WO/2024/060966A1
The present invention relates to a pan-KRAS inhibitor compound represented by formula (I), a pharmaceutical composition comprising the compound, and use of the compound of formula (I) in preventing and/or treating cancers, tumors, inflam...  
WO/2024/061298A1
The present invention relates to a heterocyclo-substituted methanone derivative and the use thereof. In particular, the present invention provides a solid form of (S)-(3-amino-5-(1-amino-1,3-dihydrospiro[indene-2,4'-piperid in]-1'-yl)pyr...  
WO/2024/057021A1
The present disclosure relates to a novel class of bifunctional molecules that are useful in a targeted or selective degradation of a protein.  
WO/2024/059563A1
Provided herein are compounds and methods for the treatment of cancer. The methods include administering to a subject in need a therapeutically effective amount of a cyclic sulfonamide RNR inhibitor disclosed herein.  
WO/2024/055196A1
The present invention relates to an acceptor-donor-acceptor (A-D-A) type organic compound and a preparation method therefor. The material has a thermal activation delayed fluorescence property; a monomolecular structure presents a face-t...  
WO/2024/059010A1
The present application relates to compounds of Formula (A), as defined herein, and pharmaceutically acceptable salts thereof, as well as processes for preparing compounds of Formula (A), and pharmaceutically acceptable salts thereof. Th...  
WO/2024/059798A1
A composite material, comprising one or more thiazolothiazole (TTz) compounds and one or more matrix materials is described herein. In another aspect, a sensor comprising a composite material comprising one or more thiazolothiazole (TTz)...  
WO/2024/059524A1
The invention provides pyrazolylcarboxamide compounds, pharmaceutical compositions, their use for inhibiting mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1), and their use in the treatment of a disease or condi...  
WO/2024/054851A1
The present disclosure includes, among other things, macrocyclic CFTR modulators of formula I, pharmaceutical compositions, and methods of making and using the same.  
WO/2024/054840A1
The present disclosure includes, among other things, compounds of formula I (I) as CFTR modulators, pharmaceutical compositions, and methods of making and using the same.  
WO/2024/051778A1
Provided herein are compounds having a Formula II-4, or a pharmaceutically acceptable salt thereof. Also provided herein are methods of preparing the compounds and methods of using the compounds in inhibiting PI3K in a cell, or in treati...  
WO/2024/051784A1
Provided are a nitrogen-containing heterocyclic compound, a pharmaceutical composition thereof, and use thereof. The structure of the nitrogen-containing heterocyclic compound is represented by formula I. The nitrogen-containing heterocy...  
WO/2024/053350A1
The purpose of the present invention is to provide a method for producing an aminoazide compound and a diamine compound in which the formation of undesired diastereomers is inhibited and which has good diastereoselectivity. Provided is a...  
WO/2024/051702A1
The present invention relates to a compound used as an inhibitor of a CDK4 kinase and use thereof. Specifically, the compound of the present invention has a structure represented by formula (I), wherein the definitions of each group and ...  

Matches 1 - 50 out of 8,204